Journal of Clinical and Aesthetic Dermatology最新文献

{"title":"Effect of Topical Microencapsulated Benzoyl Peroxide on the Skin Microbiome in Rosacea: A Randomized, Double-Blind, Crossover, Vehicle-Controlled Clinical Trial.","authors":"Yvonne Nong, Jeffrey Sugarman, Jean Philippe York, Ofra Levy-Hacham, Dawnica Nadora, Rinat Mizrahi, Aidan Galati, Richard L Gallo, Raja K Sivamani","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>We sought to evaluate changes in microbiome biodiversity and physical properties of the skin after eight weeks of once-daily topical microencapsulated benzoyl peroxide (E-BPO) compared to vehicle cream in participants with rosacea.</p><p><strong>Methods: </strong>This was a randomized, double-blind, crossover, single-center, vehicle-controlled evaluation of E-BPO on the skin microbiome in rosacea. Participants had facial rosacea with global severity of 3 or 4 on the Investigator Global Assessment (IGA) scale. In the Treatment 1-2 group, participants received E-BPO for eight weeks then switched to vehicle cream for four weeks. In the Treatment 2-1 group, participants received vehicle cream for eight weeks, then E-BPO for four weeks.</p><p><strong>Results: </strong>Thirty-one participants were enrolled and randomly assigned to either group. Demographic characteristics were comparable between the treatment groups. After eight weeks of E-BPO treatment, there was a marked reduction in the relative abundance of <i>Staphylococcus</i> accompanied by an increase in <i>Cutibacterium</i>. At the species level, there was an increase in the relative abundance of <i>C. acnes</i> and a decrease in abundance of <i>S. epidermidis</i>. No noticeable difference was detected at the genus or species level at Week 8 in the 2-1 group. Sebum level, IGA, lesion counts, facial erythema, and inflammatory scores were improved with E-BPO versus vehicle cream. Adverse events were mild or moderate in severity.</p><p><strong>Limitations: </strong>The study included a small number of subjects and only surface-swabs were used for microbiome sampling.</p><p><strong>Conclusion: </strong>E-BPO shifted the skin microbiome in rosacea and demonstrated improvements in clinical symptoms and skin physical properties and a well-tolerated safety profile. US National Library of Medicine; Trial ID: NCT05675501]; URL: clinicaltrials.gov.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 8","pages":"19-26"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronizing the Nomenclature Surrounding Synchronous Primary Cutaneous Melanomas: A Systematic Review.","authors":"Justin W Marson, Rebecca M Chen, Alisen Huang, Todd Wechter, Amor Khachemoune","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>There is little consensus regarding the nomenclature and prognostic implications of synchronous melanomas. Here, we present a case of synchronous cutaneous melanoma and perform a systematic review of similar cases in the literature.</p><p><strong>Methods: </strong>Pubmed and EMBASE databases were queried for relevant English-language articles published from inception until 2023. Cases of \"multiple primary cutaneous melanomas\" that occurred within a time frame of three months or less were included. Exclusion criteria included non-cutaneous melanomas and cases without specific time intervals or those occurring beyond a three-month period. Data including patient age, sex, risk factors, cutaneous melanoma (CM) anatomic location, CM clinicohistologic features, and prognosis were extracted from relevant articles.</p><p><strong>Results: </strong>Nineteen case reports/series documenting 22 patients with multiple primary melanomas (MPM) occurring within a three-month interval. Overall, 66 melanomas were diagnosed, with an average of three (SD±2.1, median: 2) per patient. A majority (63%) of patients had one or more risk factors for skin cancer. Subsequent CM found within three-month interval were thinner than the first found (index) CM, more likely to be melanoma <i>in situ</i> (MMis) and have highest degree of anatomic concordance if the index lesion was first found on the trunk (50%). Two retrospective cohort studies (n=4,703; n=13) of melanomas occurring within three-month interval found similar results.</p><p><strong>Limitations: </strong>Limitations to our review included inconsistent reporting in the literature and use of terminology and a limited number of case reports and case series found in the literature.</p><p><strong>Conclusion: </strong>Synchronous primary cutaneous melanomas are a heterogenous collection of terminologies that may limit the ability of dermatologists to accurately diagnose, prognosticate, and treat high-risk patients. Given lack of guidelines, we recommend the use of the term \"synchronous\" to delineate additional primary cutaneous melanomas found within a three-month interval.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 8","pages":"44-49"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11324189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth in the Cost of Biologics in Medicare Beneficiaries, 2017 to 2019.","authors":"Jennifer Laborada, Leah Shin, Claudia Lee, Shahin Shahsavari, Alexander Egeberg, Jashin J Wu","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7","pages":"17-18"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238709/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selected Abstracts from Elevate-Derm East Conference.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7-8 Suppl 1","pages":"S26-S35"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mohs Micrographic Surgery Tourism: Can We Accurately Verify Credentials of International Surgeons?","authors":"Juan Pinto-Cuberos, Frank Winsett, Andrew Armenta, Richard F Wagner","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overburdened and Undertreated: Hidradenitis Suppurativa in Skin of Color.","authors":"Archana M Sangha","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7-8 Suppl 1","pages":"S38-S39"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet-Rich Plasma for the Treatment of Atopic Dermatitis: A Literature Review.","authors":"Shifa Nurzahra Zaki, Mardyansyah, Caroline Oktarina, Reza Yuridian Purwoko, Hans Utama Sutanto","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease which is associated with a significantly decreased quality of life. Overall, the conventional treatment approaches for moderate to severe AD are prone to relapses. Hence, the exploration of new adjuvant therapies, such as the use of platelet-rich plasma (PRP), is expected to enhance the effectiveness of existing interventions, which remain paramount in improving the quality of life for patients with moderate to severe relapsing AD.</p><p><strong>Methods: </strong>The literature search primarily focused on original English-language articles on PRP as a therapeutic approach for the management of adult AD. Literature reviews, systematic literature, and meta-analyses were excluded. The databases searched include PubMed/Medline, Science Direct, and Cochrane, up to October 2023. Seven articles were reviewed.</p><p><strong>Results: </strong>PRP is reported to be used as a therapy for AD in both injectable and topical forms. Various studies showed that PRP could significantly reduce free radical accumulation, proinflammatory mediators, provide healing environment, and restore the metabolic activity disruption. Clinically, PRP therapy was reported to improve clinical symptoms, patient's satisfaction, quality of life, and reduce frequent recurrence. Mild side effects (pain and ecchymosis) due to the injection were reported. Another advantage is that it is safe to be used in pregnant and breastfeeding women.</p><p><strong>Limitations: </strong>Heterogeneity of methods in preparing PRP and further research with larger scale standardized protocols are warranted.</p><p><strong>Conclusion: </strong>PRP yields favorable outcomes when used in AD treatment and can serve as an alternative for moderate to severe or refractory AD through its anti-inflammatory and proliferative properties.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7","pages":"43-49"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of Statistical Considerations and Data Imputation Methodologies in Psoriasis Clinical Trials.","authors":"Douglas DiRuggiero, Cynthia Trickett, Lauren Hippeli, Sang Hee Park, Amy Baum-Jones, David S Davidson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Numerous clinical trials have established that various biologic and oral small-molecule therapies are efficacious in patients with psoriasis. However, as there are limited head-to-head trials, healthcare providers may compare results across multiple trials when providing treatment recommendations. Direct comparisons among agents are challenging because psoriasis trials differ in terms of study design, patient population, and data analysis methodologies. Long-term clinical trials present additional challenges because the number of patients enrolled generally declines over time. The missing patient data that might occur, coupled with the specific approach used to substitute or impute that missing data, might introduce bias and skew efficacy results. In this review, we discuss how variations in study design and analytical methodologies affect efficacy outcomes in clinical trials. We also review published trials of biologic and oral small-molecule therapies for psoriasis to illustrate how issues related to missing data and choices in data imputation methodologies can affect the interpretation of efficacy outcomes. Imputation methodologies discussed include nonresponder imputation, modified nonresponder imputation, treatment failure rules, last observation carried forward, modified baseline observation carried forward, and multiple imputation. This review provides a foundation for the healthcare provider's critical evaluation of the psoriasis literature and emphasizes the importance of considering the level of evidence provided in a clinical trial when making treatment decisions.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7-8 Suppl 1","pages":"S15-S24"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11753760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143030172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case Series of 36 Patients Treated for Old World Cutaneous leishmaniasis.","authors":"Zahra Saffarian, Zahra Vasfi Marandi, Safoura Shakoei, Shahin Hamzelou, Sima Rafati","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous leishmaniasis is endemic in Iran.</p><p><strong>Objective: </strong>We sought to investigate the therapeutic outcomes and complications of treatment in patients with cutaneous leishmaniasis.</p><p><strong>Methods: </strong>This case series enrolled patients with smear-proven cutaneous leishmaniasis who visited our center in Iran from 2018 to 2019.</p><p><strong>Results: </strong>In total, 36 patients were treated with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B. Overall, this treatment was effective in 81.8 percent of patients. Relapse and treatment failure occurred in 6.1 percent and 12.1 percent of patients, respectively. Treatment with intralesional meglumine antimoniate, intramuscular meglumine antimoniate, sodium stibogluconate, and amphotericin B yielded a clearance rate of 80.8 percent, 92.3 percent, 75 percent, and 85.7 percent, respectively. Clearance was associated with a shorter time interval between injections of intralesional meglumine antimoniate (<i>p</i>=0.006) and relapse was associated with a longer time interval between injections (<i>p</i>=0.018). The average number of side effects per patient for intralesional meglumine antimoniate, sodium stibogluconate, intramuscular meglumine antimoniate, and amphotericin B was 0.62, 1.4, 1.6, and 2.8, respectively. The most common side effect of intralesional meglumine antimoniate, intramuscular meglumine antimoniate, and amphotericin B was local pain, arthralgia, and hypokalemia, respectively.</p><p><strong>Limitations: </strong>Low sample size was the limitation of this study.</p><p><strong>Conclusion: </strong>The cure rate of intramuscular meglumine antimoniate was higher than amphotericin B, which was higher than the cure rate of sodium stibogluconate. In patients treated with intralesional meglumine antimoniate, reducing the time interval between injections increased the clearance rate and decreased the rate of relapse.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7","pages":"38-42"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examination of a Novel Intervention Strategy to Promote Sunscreen Use: A Feasibility Study.","authors":"Jessica G Irons, Noah D Gustin, Rachel E Zindler, Morgan L Ferretti","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Skin cancer remains prevalent despite numerous studies reporting the benefits of sunscreen for reducing risk of skin cancer and sunburn. While the risks of not wearing sunscreen are well-documented, there are no effective interventions to promote sunscreen use across populations, and existing interventions have modest outcomes. The current study investigated a novel intervention to increase sunscreen use.</p><p><strong>Methods: </strong>Participants (n=15) first reported their baseline daily sunscreen use then completed sunscreen sampling and selection procedures that included testing sunscreen samples, choosing preferred sunscreens to take home and sample further, and ultimately selecting a preferred sunscreen to use for the remainder of the study. Participants then self-reported their daily sunscreen use for approximately two weeks (+/-5 days).</p><p><strong>Results: </strong>All participants increased sunscreen use following intervention.</p><p><strong>Limitations: </strong>Data were collected between January and May; individuals may increase sunscreen use as temperatures increase (and time outdoors increases). Additionally, the current study relied on self-report of sunscreen use primarily.</p><p><strong>Conclusion: </strong>Our findings suggest that sampling and election procedures may be an effective strategy to promote sunscreen use. The findings of this study may inform future research examining sunscreen intervention strategies.</p>","PeriodicalId":53616,"journal":{"name":"Journal of Clinical and Aesthetic Dermatology","volume":"17 7","pages":"20-22"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11238707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}